文献速递血栓与止血

E3泛素连接酶Casitas B系淋巴瘤-b通过磷酸肌醇3-激酶信号调节免疫性血小板减少症患者的T细胞失能抵抗

E3 ubiquitin ligase casitas B-lineage lymphoma-b modulates T-cell anergic resistance via phosphoinositide 3-kinase signaling in patients with immune thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2024-01-04

该研究通过定量蛋白质组学分析免疫性血小板减少症(ITP)患者CD4+ T细胞,发现其失能诱导抵抗、磷酸肌醇3-激酶-AKT信号高度活化、CBLB表达降低及CBLB的5'非翻译区高甲基化。过表达CBLB可减弱升高的磷酸化AKT水平和失能抵抗。低剂量地西他滨治疗使7例部分或完全缓解患者的CD4+ T细胞CBLB表达显著升高。

要点

  • ITP患者CD4+ T细胞呈现失能抵抗、PI3K-AKT信号高度活化及CBLB表达降低。
  • CBLB的5'非翻译区高甲基化与ITP患者T细胞失能抵抗相关。
  • 过表达CBLB可减弱升高的磷酸化AKT水平及失能抵抗。

核心结论

  • ITP患者CD4+ T细胞中CBLB的5'非翻译区高甲基化诱导T细胞失能抵抗。
  • 低剂量地西他滨上调CBLB表达可能代表ITP的潜在治疗方法。

研究设计与样本

  • 研究纳入免疫性血小板减少症患者,采用定量蛋白质组学分析CD4+ T细胞。
  • 用腺病毒载体过表达CBLB以明确其对ITP患者T细胞失能诱导的影响。
  • 通过MassARRAY EpiTYPER检测患者CD4+ T细胞中CBLB启动子及5'非翻译区的DNA甲基化水平。

主要发现

  • ITP患者CD4+ T细胞表现为失能诱导抵抗、磷酸肌醇3-激酶-蛋白激酶B(AKT)信号高度活化、CBLB表达降低及CBLB的5'非翻译区高甲基化。
  • T细胞中过表达CBLB有效减弱了升高的磷酸化蛋白激酶B水平和失能抵抗。
  • 低剂量地西他滨治疗使7例部分或完全缓解患者的CD4+ T细胞CBLB表达水平显著升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The E3 ubiquitin ligase casitas B-lineage lymphoma-b (CBLB) is a newly identified component of the ubiquitin-dependent protein degradation system and is considered an important negative regulator of immune cells. CBLB is essential for establishing a threshold of T-cell activation and regulating peripheral T-cell tolerance through various mechanisms. However, the involvement of CBLB in the pathogenesis of immune thrombocytopenia (ITP) is unknown. OBJECTIVES: We aimed to investigate the expression and role of CBLB in CD4+ T cells obtained from patients with ITP through quantitative proteomics analyses. METHODS: CD4+ T cells were transfected with adenoviral vectors overexpressing CBLB to clarify the effect of CBLB on anergic induction of T cells in patients with ITP. DNA methylation levels of the CBLB promoter and 5' untranslated region (UTR) in patient-derived CD4+ T cells were detected via MassARRAY EpiTYPER assay (Agena Bioscience). RESULTS: CD4+ T cells from patients with ITP showed resistance to anergic induction, highly activated phosphoinositide 3-kinase-protein kinase B (AKT) signaling, decreased CBLB expression, and 5' UTR hypermethylation of CBLB. CBLB overexpression in T cells effectively attenuated the elevated phosphorylated protein kinase B level and resistance to anergy. Low-dose decitabine treatment led to significantly elevated levels of CBLB expression in CD4+ T cells from 7 patients showing a partial or complete response. CONCLUSION: These results indicate that the 5' UTR hypermethylation of CBLB in CD4+ T cells induces resistance to T-cell anergy in ITP. Thus, the upregulation of CBLB expression by low-dose decitabine treatment may represent a potential therapeutic approach to ITP.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Liu L, Xiang Y, Shao L, et al. E3 ubiquitin ligase casitas B-lineage lymphoma-b modulates T-cell anergic resistance via phosphoinositide 3-kinase signaling in patients with immune thrombocytopenia. J Thromb Haemost. 2024. PMID: 38184203. doi:10.1016/j.jtha.2023.12.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。